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ABSTRACT Adenosine acts as a neuromodulator in the hippocampus essentially through activation of
inhibitory A1 receptors. Using single-cell PCR analysis, we found that CA1 pyramidal cells coexpress A1
receptor mRNA together with that of another adenosine receptor, the A3 receptor. As occurs for the A1
receptor, Western blot analysis indicated that the A3 receptor is also located in hippocampal nerve
terminals. However, activation of A3 receptors with its purportedly selective agonist Cl-IBMECA (0.1–10
mM) failed to affect hippocampal synaptic transmission or to modify the evoked release of glutamate or
GABA. Also, blockade of A3 receptors with MRS 1191 (5 mM) failed to affect either hypoxia- or ischemia-
induced depression of hippocampal synaptic transmission. Activation of A3 receptors also failed to control
A1 receptor function, as Cl-IBMECA (100 nM) did not modify the ability of CPA to displace [
3H]DPCPX
binding to hippocampal membranes or the A1 receptor-mediated inhibition of hippocampal synaptic
transmission. However, ligand binding studies revealed that Cl-IBMECA displaced the binding of an A1
receptor agonist ([3H]R-PIA, Ki¼ 47 nM) or antagonist ([
3H]DPCPX, Ki¼130 nM), which suggests that A3
receptor ligands also act on native A1 receptors. We believe that A3 receptors are expressed in
hippocampal neurons and are located in hippocampal nerve terminals, though their function remains
elusive. Drug Dev. Res. 58:428–438, 2003. c 2003 Wiley-Liss, Inc.
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Adenosine is believed to act as a neuroprotective
agent by activation of each of the four cloned and
pharmacologically characterized adenosine receptors
(A1, A2A, A2B, and A3) [Fredholm, 1996]. For example,
the most recently cloned A3 receptor has been reported
to have a profound effect on the outcome of ischemic
insults [reviewed by von Lubitz et al., 2001] and to
protect against chemotoxicity [Fishman et al., 2001]
and apoptotic cell death, namely in astrocytes [Ab-
bracchio et al., 1998] and neurons [Sei et al., 1997]. It
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has been argued that A3 receptors have an affinity for
adenosine considerably lower (Ki=1000 nM) than A1
(Ki=10 nM) and A2A (Ki=30 nM) receptors [Gallo-
Rodriguez et al., 1994]. This implies that the activation of
A3 receptors is essentially predicted to occur in stressful
situations that lead to a marked increase in the
extracellular concentration of adenosine [Jacobson,
1998]. However, more recent data indicate that adeno-
sine is as potent on A3 as on A1 and A2A receptors
[Fredholm et al., 2001; Schulte and Fredholm, 2001].
Whether A3 receptors might also control neuronal
activity under nonstressful situations is not clear because
the effects of A3 receptor activation on neuronal activity
at the cellular level have been poorly investigated. In the
cerebral cortex, the A3 receptor agonist IB-MECA
inhibited synaptic transmission in a manner sensitive to
an A3 receptor antagonist [Brand et al., 2001]. In the
hippocampus, A3 receptor activation facilitates synaptic
plasticity phenomena [Costenla et al., 2001] and
increases neuronal activity through a protein kinase A-
dependent facilitation of postsynaptic calcium currents
[Fleming and Mogul, 1997], although A3 receptors
appear not to affect calcium-activated potassium currents
[Dunwiddie et al., 1999]. In the hippocampus, A3
receptor immuno-reactivity was identified in nerve
terminals [Dı´az-Herna´ndez et al., 2002] and the activa-
tion of these putative presynaptic A3 receptors inhibits
both metabotropic glutamate group III receptor- [Macek
et al., 1998] and adenosine A1 receptor-mediated
responses [Dunwiddie et al., 1997].
In spite of these evidences for both presynaptic
and postsynaptic A3 receptor-mediated effects in the
central nervous system, the density of A3 receptors in
the brain is rather low and the identification of A3
receptors has mostly been accessed by whole-tissue
PCR, which has revealed the presence of mRNA
encoding for A3 receptor in the hippocampus, cere-
bellum, and striatum [De et al., 1993; Dixon et al., 1996;
Richardson et al., 2000]. However, in situ hybridization
studies have questioned whether neurons in the brain
expressed A3 receptors [Rivkees et al., 2000].
Thus, we now took advantage of single-cell PCR and
combined biochemical and immunological techniques to
test if hippocampal neurons are endowed with A3
receptors. We tried to define the possible role of A3
receptors in the hippocampus in nonstressful and in
stressful situations, with particular attention to whether A3
receptors control the predominant adenosine A1 receptors.
MATERIALS AND METHODS
Single-Cell PCR
Sections 10 mm thick from male Wistar rats frozen
brains were obtained with a cryostat, taken between
4.52 and 2.80 mm from Bregma, dehydrated in
100% ethanol, rehydrated gradually (50–100% etha-
nol), stained with Nissl stain (gives purple color to
neurons), and dehydrated again with xylene according
to Luo et al. [1990]. The required neurons from CA1
area of the hippocampus were laser microdissected
with an Arcturus LCM 210 PixCell II system with a
spot size of 7.5 mm. The total RNA was then extracted
according to Absolutely RNA Nanoprep Kit instruc-
tions from Stratagene and subjected to reverse
transcription (RT) and cDNA amplification. For RT
and cDNA amplification, we used the 30-end amplifica-
tion (TPEA) protocol previously described by Dixon et
al. [1998]. All the primers used were from Perkin
Elmer Applied Biosystems (United Kingdom). The
amplified samples (5 ml aliquots) were used for
subsequent gene-specific PCR after cDNA purification
according to QIAquick spin handbook (QIAGEN). For
gene-specific PCR, the samples of the preamplified
cDNA were subjected to 45 rounds of PCR in 20 mL of
45 mM Tris-HCl (pH 8.1), 12.5% (w/v) sucrose, 12 mM
(NH4)2SO4, 3.5 mM MgCl2, and 0.5 mM deoxynucleo-
tide triphosphates, with 100 ng of the forward and
reverse primer. The cycling conditions were 2.5 min at
921C (denaturation), 1.5 min at 601C (annealing), and 1
min at 721C (extension). After amplification, the
products were separated on 2% agarose gels and
visualized using ethidium bromide. The primers used
are listed in Table 1. In all experiments, positive
controls for the primers used were electrophoresed in
parallel to the gene-specific assays. These routinely
contained cDNA derived from 1 ng of whole-brain
total RNA.
Western Blot Analysis in Nerve Terminal Membranes
The Western blot analysis of A3 receptors was
carried out in membranes from a Percoll-purified
synaptosomal fraction, prepared as previously de-
scribed [Cunha et al., 1996]. After determining the
amount of protein [Spector, 1978], each sample was
diluted with an equal volume of 2 SDS-PAGE
sample buffer (62.5 mM Tris-HCl pH 6.8, 25% (v/v)
glycerol, 2% (w/v) SDS, 0.01% (w/v) bromophenol
blue, 5% (v/v) b-mercaptoethanol). These diluted
samples and the prestained molecular weight markers
(Amersham) were separated by SDS-PAGE (10%
resolving gel and 4% concentrative gel) under reducing
conditions and electrotransferred to polyvinylidene
difluoride membranes (0.45 mm from Amersham).
After blocking for 2 h at room temperature with 5%
milk in Tris-buffered saline (140 mM NaCl, 20 mM
Tris), pH 7.6 containing 0.1% Tween 20 (TBS-T), the
membranes were incubated overnight at 41C with a
rabbit anti-adenosine A3 receptor affinity purified
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polyclonal antibody (Chemicon, 1 mg/mL, 1:1000
dilution). After four 10-min washes with TBS-T
containing 0.5% milk, the membranes were incubated
with the alkaline phosphatase-conjugated anti-rabbit
secondary antibody (1:5000 dilution from Amersham)
in TBS-T containing 1% milk during 90 min at room
temperature. After five 10-min washes in TBS-T
containing 0.5% milk, the membranes were incubated
with Enhanced Chemi-Fluorescence (ECF) for 5 min
and then analyzed densitometrically with a Storm
(Molecular Devices).
Electrophysiological Recordings in Hippocampal
Slices
Male Wistar rats (5–6 weeks old), handled
according to the European guidelines (86/609/ EEC),
were decapitated after halothane anesthesia, and the
hippocampus dissected free in ice-cold Krebs solution
of the following composition (mM): NaCl 124, KCl 3,
NaHCO3 26, Na2HPO4 1.25, MgSO4 1, CaCl2 2,
glucose 10, gassed with a 95% O2 + 5% CO2 mixture.
Slices were cut (400 mm) with a McIlwain tissue
chopper and allowed to recover for at least 1 h in a
resting chamber within the same gassed medium at
room temperature (20–251C). Individual slices were
transferred to a submersion recording chamber (1 mL
capacity) and continuously superfused at a rate of 3
mL/min with the same gassed Krebs solution at 30.51C
or at 321C for hypoxia and ischemia experiments.
Stimulation was delivered to the Schaffer collateral/
commissural fibers through a bipolar concentric wire
electrode and rectangular pulses of 0.1 ms duration
were applied every 15 sec. The initial intensity of the
stimulus was chosen to elicit a response of about 50%
of maximal field excitatory postsynaptic potencial
(fEPSP) amplitude. The fEPSPs were recorded extra-
cellularly from CA1 stratum radiatum by use of
micropipettes filled with NaCl 4 M with 2–4 MO
resistance, and displayed on a Tektronix digitizing
oscilloscope. The averages of eight consecutive re-
sponses were obtained, graphically plotted, and
recorded for further analysis with the LTP software
[Anderson and Collingridge, 1997]. The slopes and
amplitudes of the averaged fEPSPs were determined
and then averaged during the predrug control, drug
superfusion, and postdrug washout period; at least six
responses were included in each average. Compounds
were added through the superfusion solution.
The hypoxic insult consisted of changing the
superfusion tube to a Krebs solution in which
the bubbling gas was 95% N2+5% CO2 for 4 min and
the maximum depression in amplitude of the fEPSPS
registered. The ischemic insult was achieved by
changing for 10 min the superfusion tube to a Krebs
solution, but where glucose was not present, gassed
with 95% N2+5% CO2. After the challenging periods,
the superfusion solutions were changed back to normal
Krebs solution. The data were analyzed as mean
percentage change in response amplitude when
compared with responses obtained during the control
period. The values are shown as mean 7 SEM of n
(number of experiments), except where otherwise
indicated. The significance of differences was evaluated
by the paired Student’s t test. P values less than 0.05
were considered significant.
Neurotransmitter Release from Hippocampal Nerve
Terminals
The evoked release of [3H]glutamate was carried
out as previously described [Lopes et al., 2002], and the
release of [3H]GABA was performed as described by
Cunha and Ribeiro [2000]. Synaptosomes were pur-
ified by sucrose/Percoll gradients, loaded with [3H]glu-
tamate or [3H]GABA, and placed over GF/B filters
under superfusion. The synaptosomes were stimulated
twice with 20 mM K+ for 30 sec (for glutamate release)
or for 2 min (for GABA release) with a time span of
9–16 min. Drugs were added 2 min before the second
stimulation period, and their effect was evaluated by
changes in the evoked release of tritium measured in
the effluent.
Membrane Binding Experiments
Either membranes or synaptosomes were pre-
pared as previously described [Lopes et al., 1999].
Competition curves of the adenosine A1 receptor
antagonist [3H]DPCPX by the adenosine A1 receptor
agonist CPA were performed in the absence and in the
TABLE 1. PCR Primers Used
Name Abbreviation Gene name Primers PCR product length (bp)
Glial fibrillary acidic protein GFAP 68–87, 216–198 170
Intronic marker ET3 Region chromosome 3 149
Adenosine receptors:
A1 A1 Adora1 1225–1242, 1392–1373 168
A3 A3 Adora3 1590–1608, 1739–1719 150
NMDA receptor subunit 1 NR1 Grin1 3941–3932, 4091–4074 178
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presence of the adenosine A3 receptor agonist Cl-
IBMECA. Competition curves of the A1 receptor
antagonist [3H]DPCPX, and of the A1 receptor agonist
[3H]PIA by the A3 agonist Cl-IBMECA, were also
performed. The appropriate synaptosome or mem-
brane preparation (120 mL containing 165–331 mg
protein) was incubated with either [3H]DPCPX (2 nM)
or [3H]R-PIA (2 nM) and 10 different concentrations
of the displacer Cl-IBMECA (ranging from 0.1 nM to
10 mM) or CPA (ranging from 0.1 nM to 1 mM) in 50
mM Tris and 2 mM MgCl2, pH 7.4 (if membranes) or
Krebs solution (if synaptosomes) in a final volume of
300 mL. All samples were assayed in triplicate.
Nonspecific binding was evaluated in the presence of
2-chloroadenosine (CADO, 100 mM) and represented
10–15% of total binding. The test tubes were incubated
for 2 h at room temperature (20–251C) for [3H]DPCPX
binding or 2 h at 371C for [3H]R-PIA binding. The
binding reactions were stopped by vacuum filtration
through glass fiber filters (filtermats to receptor
binding from Skatron) using a Skatron 1719 cell
harvester, and the tubes and filters washed with 5 mL
of the respective ice-cold incubation buffer. The filters
were then placed in scintillation vials and 4 mL of
scintillation liquid (Optiphase HiSafe Scintillation
Cocktail) added. Radioactivity was determined after at
least 12 h with a counting efficiency of 55–60%. The
protein concentration was determined using the Bio-Rad
protein assay [Bradford, 1976]. The IC50 values were
converted into Ki values upon nonlinear fitting of the
semilogaritmic curves derived from the competition
curves. An F test (P o 0.05) was used to determine
whether the competition curves were best fitted by a one
or two independent binding site equation. The Ki values
are presented as mean with 95% confidence interval (CI).
Autoradiographic Experiments
Six mice of each genotype, wild-type (A3R
(+/+)),
heterozygous (A3R
(+/)), and mice lacking the A3
receptor (A3R
(/)), on a 129/B6D2 background
[Salvatore et al., 2000] (generation F2 or F3), were
anesthetized with carbon dioxide and thereafter
decapitated. The brains were immediately dissected
out, frozen on dry ice, and stored at 801C until used.
Using a cryostat, the levels of Bregma 1.42 to 0.50,
0.34 to 0.58, 1.70 to 2.18, and 7.08 to 7.48
mm [Franklin and Paxinos, 1997] were sectioned into
10-mm-thick frontal sections, which were thaw moun-
ted on polylysine-coated glass slides (Menzel-Gla¨ser,
Germany). Slides were stored at 201C until used.
Receptor autoradiography was performed by
drying the sections at room temperature for 60 min
and preincubating at 371C in 170 mM Tris-HCl, 2 U/
mL adenosine deaminase (ADA) and 1 mM EDTA, pH
7.4, for 30 min. After washing twice at room
temperature in 170 mM Tris-HCl with 1 mM MgCl2
(pH 7.4) for 10 min, the sections were incubated for 2 h
at room temperature in a solution containing 170 mM
Tris-HCl (pH 7.4), 1 mM MgCl2, 2 U/mL ADA, and
0.2, 0.5, 1, 2, 5, or 10 nM [3H]DPCPX, and for
nonspecific binding, 20 mM R-PIA. The slides were
then washed twice in 170 mM Tris-HCl (pH 7.4) at 41C
for 5 min and dipped three times in ice-cold distilled
water. Slides were dried overnight in front of a fan at
41C. Sections were then apposed to Hyperfilm-3H
(Amersham) together with tritium standards (Amer-
sham) for 3 weeks. The optical density was measured
using a computer program (MCID, Imaging Research,
St. Catherines, Canada), and values were converted to
fmol/mg grey matter using the tritium standards. The
specific binding was achieved by subtracting the
nonspecific binding from the total binding values.
Compounds
3-Ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-
phenyl-1,4-(7)-dihydropyridine-3,5- dicarboxylate (MRS
1191), N6-cyclopentyladenosine (CPA), and 1,3-dipro-
pyl-8-cyclopentylxanthine (DPCPX) were purchased
from Sigma-RBI (Natick, USA). 1-[2-Chloro-6-[[(3-
iodophenyl)methyl]amino]-9H-purin-p-yl]-1-deoxy-N-
methyl-b-d-ribofuranuronamide (2-Cl-IBMECA) and
4-(2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3-a}{1,3,5}triazin-
5-yl-amino]ethyl)phenol (ZM 241385) were from
Tocris (Bristol, UK). 2-Chloroadenosine was from the
Sigma (Poole, Dorset, UK). [3H]DPCPX (specific
activity: 110.6 Ci/mmol) was from DuPont-NEN
(Stevenage, UK) and adenosine deaminase (from calf
intestine, 200 U/mg protein, 2 mg/10 mL solution in
50% glycerol (v/v), 10 mM potassium phosphate, pH
6.0] was from Boehringer (Manheim, Germany).
[3H]glutamate (specific activity: 45 Ci/mmol),
[3H]GABA (specific activity: 76.2 Ci/mmol), and
[3H]R-phenylisopropyladenosine ([3H]R-PIA; specific
activity: 63 Ci/mmol) were from Amersham (Buck-
inghamshire, UK). All drugs were diluted daily into the
appropriate media from 5 mM stock solutions made up
in dimethylsulfoxide stored at 201C, except adenosine
deaminase, [3H]R-PIA and [3H]DPCPX, which were
prepared directly into the incubation solution each day.
DPCPX was made up as a 5 mM stock solution in
dimethylsulfoxide 99% (v/v) containing 0.01 M NaOH.
RESULTS
Presence of Adenosine A3 Receptors in Hippocampal
Neurons Together with A1 Receptors
Taking advantage of laser dissection, which allows
isolated cells to be taken from heterogeneous tissue
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with little contamination from the surroundings, we
dissected single pyramidal neurons from the CA1 area
of the hippocampus and subjected them to gene-
specific PCR. In addition to the adenosine receptors
mRNAs, we also tested NMDAR1, a marker of
pyramidal cells, GFAP, an astrocyte marker, and one
intronic marker to ensure the quality of the RT
reaction. From 10 cells analyzed that were
NMDAR1-positive, five of them showed coexpression
of mRNA encoding for adenosine A1 and A3 receptors
(see Fig. 1A). We are aware that contamination from,
for example, microglial processes cannot be excluded.
Given this apparent coexpression of A1 and A3
receptor mRNA in pyramidal cells, we looked for the
presence of A3 receptors where A1 receptors are most
abundant (i.e., in nerve terminals). As illustrated in
Figure 1B, there was a clear A3 receptor-like immunor-
eactivity that displayed an electrophoretic mobility
corresponding to an apparent molecular weight of 44
kDa, similar to the expected molecular weight of the
rat A3 receptor [Christofi et al., 2001]. This signal was
not observed either when the primary antibody was not
added or when this experiment was carried out in the
presence of 1 mg of the immunizing peptide.
Effects of A3 Receptors on Synaptic Transmission and
Neurotransmitter Release
The purportedly more selective adenosine A3
receptor agonist available, Cl-IBMECA, did not affect
synaptic transmission in the concentration range tested
(10 nM to 10 mM) (Fig. 2). This lack of effect of A3
receptor activation could be caused by opposite effects
on glutamate and GABA release. We therefore
evaluated the effect of A3 receptor activation on
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Fig. 2. Effect of an A3 receptor agonist Cl-IBMECA on synaptic
transmission in rat hippocampal slices. (A) Time course of the
averaged slope of eight consecutive fEPSPs in a representative
experiment where a hippocampal slice was successively superfused
with increasing concentrations of Cl-IBMECA at the time indicated by
the arrows. (B) Summary data showing the percentage effect of Cl-
IBMECA on synaptic transmission. Results are means 7 SE of two
experiments.
Fig. 1. Presence of adenosine A3 receptors in the hippocampus.
(A) mRNA profile for adenosine receptors in a single pyramidal neuron
from CA1 area of the hippocampus. The first lane from the left
corresponds to ladder standards: 1, A1 receptor; 2, A2A receptor; 3, A3
receptor; and 4, NMDA resceptor subunit 1. (B) Western blot analysis
of A3 receptor immuno-reactivity in membranes from purified nerve
terminals of the rat hippocampus (100 mg of membrane protein
applied to the gel).
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glutamate and GABA release from hippocampal nerve
terminals. Because we had previously observed that Cl-
IBMECA might activate adenosine A1 receptors
[Costenla et al., 2001], the following experiments were
conducted under blockade of A2A and A1 receptors to
eliminate possible nonselective responses, using the A1
receptor antagonist DPCPX (50 nM) and the A2A
receptor antagonist ZM 241385 (50 nM). Cl-IBMECA
(100 nM and 10 mM) had no effect on glutamate
release compared to control conditions (Table 2).
Likewise, 100 nM and 1 mM Cl-IBMECA failed to
modify the evoked release of GABA from superfused
hippocampal synaptosomes (see Table 2).
To test whether A3 receptors might be tonically
activated in stressful situations, we tested the con-
sequences of blocking A3 receptors on synaptic
transmission during a hypoxic insult lasting 4 min. As
illustrated in Figure 3A, the removal of oxygen causes a
marked inhibition of synaptic transmission that re-
covers completely once oxygen is reintroduced. It is
also evident from Figure 3A that the hypoxia-induced
depression of fEPSPs was similar in both the absence
and presence of the A3 receptor antagonist MRS 1191
(5 mM). The consequences of blocking A3 receptors
were also tested in an ischemic situation applied for 10
min. But again, the ischemia-induced depression of
fEPSPs was similar in the absence and in the presence
of MRS 1191 (5 mM) (Fig. 3B). In control experiments,
we confirmed that two consecutive hypoxic or ischemic
insults caused a similar depression of fEPSPs in the
absence of drugs (data not shown).
Effect of Adenosine A3 Receptor Activation on A1
Receptor Function
One possibility to reconcile the evidence for the
neuronal location of A3 receptors with the lack of effect
of A3 receptors on synaptic transmission and neuro-
transmitter release would be that the A3 receptors
mostly fulfilled a fine-tuning role, controlling the action
of other neuromodulatory systems [Sebastia˜o and
Ribeiro, 2000]. Thus, we investigated if A3 receptors
could control A1 receptor function, as previously
proposed [see Dunwiddie et al., 1997]. To carry out
this study, we first had to evaluate the real selectivity of
the most selective A3 receptor agonist, Cl-IBMECA,
against hippocampal A1 receptors, because the initial
selectivity of this ligand has mostly been determined
using heterologously expressed adenosine receptors
and previous studies have claimed that Cl-IBMECA
could bind and activate A1 receptors in the rat brain
[Rivkees et al., 2000; Costenla et al., 2001].
We performed displacement binding curves of
the adenosine A1 receptor agonist [
3H]R-PIA, and of
the adenosine A1 receptor antagonist [
3H]DPCPX by
the A3 receptor agonist Cl-IBMECA. As illustrated in
Figure 4, Cl-IBMECA (0.1 nM to 10 mM) displaced
[3H]R-PIA (2 nM) with a Ki of 47 nM (95% confidence
interval: 39–57 nM, n¼ 4) and displaced [3H]DPCPX
(2 nM) with a Ki of 130 nM (95% confidence interval:
91–190 nM, n¼ 4). Thus, to evaluate the effect of A3
receptor activation on the affinity of A1 receptors, we
tested the effect of a concentration of 100 nM of Cl-
IBMECA on the ability of the A1 receptor agonist CPA
to displace the A1 receptor antagonist [
3H]DPCPX (2
nM). These experiments were carried out in hippo-
campal synaptosomes to preserve intracellular transdu-
cing pathways eventually required for the interaction to
occur [Lopes et al., 1999]. In control conditions (i.e.,
with no Cl-IBMECA), the displacement binding curve
by CPA (0.1 nM to 1 mM) was fitted best by a single
binding site equation with a Ki of 1.4 nM (95%
confidence interval: 0.9–2.2 nM, n¼ 6) (see Fig. 4C).
Cl-IBMECA (100 nM) did not significantly (P4 0.05)
change the displacement binding curve of CPA,
resulting in a Ki of 2.3 nM (95% confidence interval:
1.7–3.2 nM, n¼ 6) (see Fig. 4C).
Because these experiments in synaptosomes were
conducted in a time scale of minutes and the A3/A1
receptor interaction could take longer to be measured,
we compared by autoradiography the binding of the
selective A1 receptor ligand [
3H]DPCPX in sections
from wild-type and A3 receptor knock-out mice. Using
mutant mice in which the gene for A3 receptor was
knocked out [Salvatore et al., 2000] or reduced by half
(A3R
(+/)), we observed that no differences existed in
the binding of DPCPX to the hippocampus, compared
to wild-type mice (Fig. 5). There was also no difference
in DPCPX binding in any other region studied
(hippocampus, cortex, cerebellum, and striatum; data
not shown). The Bmax values in the CA1 region for
TABLE 2. Effect of A3 Receptor Activation on Glutamate and GABA Release from Hippocampal Nerve Terminals
Control Cl-IBMECA (100 nM) Control Cl-IBMECA (1–10 mM)
[3H] glutamate release 0.8170.01 (n=4) 0.7470.12 (n=4) 1.170.3 (n=4) 0.970.2 (n=4)
[3H] GABA release 0.7870.04 (n=6) 0.7270.05 (n=6) 0.7370.04 (n=6) 0.7770.07 (n=6)
These experiments were conducted under blockade of A1 receptors (using DPCPX, 50 or 200 nM) and A2A receptors (using ZM 241385, 50 or
200 nM).
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A3R
(+/+), A3R
(+/), and A3R
(/) were 328.0 (95%
confidence interval: 292.1–363.9), 350.7 (317.8–
383.6), and 336.5 (306.1–366.9) fmol/mg grey matter,
respectively, and the KD values were 0.46 (95%
confidence interval: 0.25–0.67), 0.53 (0.33–0.73), and
0.48 (0.30–0.66) nM, respectively (n¼ 6 for all). In the
CA3 area, the Bmax values were 328.3 (95% confidence
interval: 290.8–365.8), 350.0 (315.3–384.6), and 323.7
(291.0–356.5) fmol/mg grey matter for A3R
(+/+),
A3R
(+/), and A3R
(/), respectively, and the KD values
were 0.53 (95% confidence interval: 0.29–0.78), 0.59
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Fig. 3. Effect of an A3 receptor antagonist on hypoxia- or ischemia-
induced depression of synaptic transmission in rat hippocampal slices.
(A) Time course of the averaged amplitude of eight consecutive fEPSPs
in a representative experiment of hypoxia-induced depression of
synaptic transmission. The hypoxia period started at the time indicated
by each arrow and lasted for 4 min. The A3 receptor antagonist MRS
1191 (5 mM) was applied during the period indicated by the horizontal
line. (B) Time course of the averaged amplitude of eight consecutive
fEPSPs in a representative experiment of ischemia-induced depression
of synaptic transmission. The ischemia period started at the time
indicated by each arrow and lasted for 10 min. The A3 receptor
antagonist MRS 1191 (5 mM) was applied during the period indicated
by the horizontal line.
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Fig. 4. Displacement binding curves of (A) [3H]R-PIA (2 nM) and (B)
[3H]DPCPX (2 nM) by Cl-IBMECA (0.1 nM to 10 mM) in hippocampal
membranes of young adult rats; (C) Displacement binding curves of
[3H]DPCPX (2 nM) by CPA (0.1 nM to 1 mM) in the absence (J) and in
the presence () of the A3 receptor agonist Cl-IBMECA (100 nM). The
ordinates represent the percentage of radioactive ligand bound
obtained on subtraction of the nonspecific binding, determined in
the presence of 100 mM CADO, from the total binding. Each point is
the mean 7 SEM of four experiments performed in triplicate. The Ki
values were obtained from the curves represented, which were fitted
to the experimental data.
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(0.36–0.82), and 0.50 (0.30–0.71) nM, respectively
(n¼ 6 for all).
Because the A3/A1 interaction was reported to
occur at the functional rather than the molecular level
[Dunwiddie et al., 1997], we used extracellular
electrophysiological recordings from CA1 area of rat
hippocampal slices to probe this interaction. We
compared the effect of the stable adenosine analogue,
2-chloroadenosine (CADO) in the absence and in the
presence of Cl-IBMECA. CADO (1 mM) alone caused
an 86.37 4.5% (n¼ 3) inhibition of fEPSP amplitude,
an effect caused by A1 receptor activation [de
Mendonc¸a and Ribeiro, 1990]. In the presence of Cl-
IBMECA (100 nM), CADO (1 mM) still reduced by
79.0 7 6.5% (n¼ 3) the fEPSP amplitude (Fig. 6), a
value similar (P 4 0.05) to that caused by the first
application of CADO (1 mM) alone in the same slices.
In control experiments, we confirmed that two
successive applications of CADO (1 mM) alone elicited
a similar inhibition of fESPS amplitude (the ratio
between CADO inhibitory effect elicited by the second
and first application was 1.02 7 0.03, n¼ 2).
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Fig. 5. The binding of [3H]DPCPX is unaffected in mice lacking A3
receptors (A3R
(/)). (A) Autoradiogram of a frontal section from a
A3R
(/) incubated with 2 nM [3H]DPCPX. There was no difference in
[3H]DPCPX binding in the hippocampus as measured in areas CA1 (B)
or CA3 (C) between the different genotypes (A3R
(/), A3R
(+/), and
A3R
(+/+)). The values presented are mean 7 SEM, n=6 for all.
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Fig. 6. Effect of A3 receptor activation on A1 receptor-mediated
responses in the hippocampus. (A) Time course of a representative
experiment. After obtaining a stable fEPSP response, CADO (1 mM)
was added to the superfusion solution and then washed out. To test the
effect of Cl-IBMECA (100 nM), this drug was added at least 30 min
before the second application of CADO. The horizontal bars represent
the period of application of each drug to the superfusion solution. (B)
Average percentage inhibition of fEPSP slope by CADO in the absence
and in the presence of Cl-IBMECA. The values are mean 7 SEM of
three experiments.
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DISCUSSION
The present results provide evidence that adeno-
sine A3 receptors are expressed in hippocampal
neurons and that they are located in hippocampal
nerve terminals. However, these presynaptic A3 recep-
tors do not have a direct effect on synaptically evoked
excitatory responses, as observed previously in the
same preparation [Dunwiddie et al., 1997] and as
reported to occur in the cortex [Brand et al., 2001].
Even in situations of cellular stress, such as hypoxia or
ischemia, when the extracellular levels of adenosine
rise [reviewed by Fredholm, 1996; Cunha, 2001], no
effect of endogenous adenosine-activating A3 receptors
could be detected in the control of synaptic transmis-
sion. Also, no effects resulting from A3 receptor
activation could be monitored in the evoked release
of glutamate or GABA from synaptosomes. These
results are in complete agreement with the recent
finding that adenosine has no effect on excitatory
neurotransmission in the hippocampus of mice that
lack the adenosine A1 receptor [Johansson et al., 2001].
This lack of evident effects of presynaptic A3
receptors also appears at odds with the previously
reported ability of A3 receptors to facilitate long-term
potentiation (LTP) and long-term depression (LTD)
[Costenla et al., 2001]. But taking the data together, it is
likely that the control by A3 receptors of synaptic
plasticity might result from the activation of post-
rather than presynaptic A3 receptors. This would
reconcile the presently observed expression of A3
receptor mRNA in hippocampal pyramidal neurons
with the previously reported ability of A3 receptors to
facilitate postsynaptic calcium currents [Fleming and
Mogul, 1997]. Further work is required to charac-
terize these postsynaptic A3 receptors in the hippo-
campus.
Thus, the possible role of the identified pre-
synaptic A3 receptors in the rat hippocampus remains
essentially elusive. It is possible that presynaptic A3
receptors might be especially important in a particular
subtype of hippocampal nerve terminals. In this
respect, it has been reported that A3 receptor activation
has a minor role in the control of serotonin release in
the hippocampus [Okada et al., 1997], but to the best of
our knowledge no information is available on the ability
of A3 receptors to control noradrenaline, dopamine, or
acetylcholine release in the hippocampus. Another
possible role for these presynaptic A3 receptors might
be their ability to act as fine-tuning neuromodulators
[Sebastia˜o and Ribeiro, 2000]. In fact, A3 receptors
have been described to inhibit the actions of group III
presynaptic metabotropic glutamate receptors in the
hippocampus [Macek et al., 1998], to inhibit adenosine
polyphosphate-mediated presynaptic calcium transi-
ents [Diı´z-Herna´ndez et al., 2002], and also to inhibit
adenosine A1 receptor-mediated responses in the rat
hippocampus [Dunwiddie et al., 1997].
We explored this possible role of A3 receptors to
attenuate A1 receptor-mediated responses [Dunwiddie
et al., 1997] and we provide the required structural
background for this interaction to occur (i.e., the
presence of mRNA for both receptor subtypes in the
same cell), as suggested by PCR analysis of a single
CA1 neuron. However, we found no apparent control
by A3 receptors of A1 receptor-mediated inhibition of
excitatory synaptic transmission or of the affinity of A1
receptors, as shown by binding studies. Also, the mice
lacking A3 receptors displayed no differences in the
number or affinity of A1 receptors, suggesting that no
long-term control by A3 receptors of the density of A1
receptors takes place. The concentration of the A3
receptor agonist Cl-IBMECA used in the present study
was lower than that used in previous studies because
recent data show a lack of selectivity of A3 receptor
agonists over A1 receptors [Rivkees et al., 2000;
Costenla et al., 2001]. We confirmed that Cl-IBMECA
binds to A1 receptors even at low nanomolar concen-
trations. This obviously compromises the possibility of
any eventual A1/A3 receptor interaction to be fully
investigated and casts strong doubts on whether the
previously reported A3/A1 receptor interaction might
result from the lack of selectivity of the A3 receptor
ligands available.
One of the key questions raised by the present
results is the usefulness of the A3 receptor ligands,
particularly Cl-IBMECA, to study A3 receptor-
mediated effects. The initial selectivity essays of Cl-
IBMECA for A3 receptors versus A1 receptors were
conducted in cortical tissue [Kim et al., 1994], which
might behave differently [cf. Brand et al., 2001 and
present data]. Also, the fact that these ligands were
synthesized based upon their potency in inhibiting
adenylate cyclase in heterologous expression systems
[Kim et al., 1994] limits the direct comparison of the
obtained parameters to native tissues, as most of
the evidence seems to indicate that A3 receptors in
the brain might not couple to adenylate cyclase but
rather to protein kinase C [Abbracchio et al., 1995;
Dunwiddie et al., 1997; Macek et al., 1998]. Thus, the
real selectivity of the currently available A3 receptor
ligands against native adenosine receptors remains to be
fully evaluated, and their use in physiological experi-
ments in native tissue must be carefully evaluated.
In conclusion, A3 receptors are present in the
hippocampus, particularly in nerve terminals, and
colocalized with A1 receptors in pyramidal neurons.
The present data suggest that no interaction between
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these two receptors subtypes exist and that A3
receptors do not affect synaptic transmission (basal or
in stressful conditions) or control glutamate or GABA
release. That the known A3 receptor ligands bind A1
receptors represents a limitation for conclusive studies.
The definititive answer to the function of A3 receptors
has to wait for reliable ligands and reliable functional
assay to be used for the pharmacological characteriza-
tion of A3 receptor ligands vis-a`-vis native A3 receptors.
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